TABLE 4.

UVA of factors associated with bilateral disease

Characteristic	Unilateral disease (n = 116)	Bilateral disease (n = 22)	p-value
Race			0.6
Asian	12 (11%)	2 (9.1%)
Black	14 (13%)	1 (4.5%)
Other	5 (4.7%)	2 (9.1%)
White	76 (71%)	17 (77%)
Unknown	9	0
Menopausal status			0.036
Pre- and peri-menopausal	91 (78%)	12 (55%)
Postmenopausal	25 (22%)	10 (45%)
Gene			0.3
ATM	38 (33%)	11 (50%)
CHEK2	49 (42%)	8 (36%)
PALB2	25 (22%)	2 (9.1%)
Multiple mutations	4 (3.4%)	1 (4.5%)
Alteration			0.3
Pathogenic	40 (34%)	11 (50%)
VUS	76 (66%)	11 (50%)
First-degree relative with breast cancer	28 (24%)	8 (36%)	0.4
Neoadjuvant chemotherapy	48 (42%)	5 (23%)	0.2
Unknown	1	0
Adjuvant chemotherapy	46 (40%)	6 (27%)	0.4
Histology			0.046
IDC	88 (76%)	11 (50%)
ILC	11 (9.5%)	6 (27%)
Invasive/other	4 (3.4%)	1 (4.5%)
DCIS	13 (11%)	4 (18%)
Receptor status			0.2
HR+/HER2−	52 (50%)	13 (72%)
HER2+	26 (25%)	4 (22%)
Triple negative	25 (24%)	1 (5.6%)
Unknown	13	4
Clinical T stage			0.5
T0/Tis	25 (22%)	8 (38%)
T1	49 (42%)	9 (43%)
T2	25 (22%)	2 (9.5%)
T3	12 (10%)	2 (9.5%)
T4	5 (4.3%)	0 (0%)
Unknown	0	1
Clinical N stage			0.9
N0	89 (77%)	16 (76%)
N1	23 (20%)	5 (24%)
N2	2 (1.7%)	0 (0%)
N3	2 (1.7%)	0 (0%)
Unknown	0	1
Type of surgery			0.5
Breast-conserving surgery	41 (35%)	10 (45%)
Mastectomy	75 (65%)	12 (55%)
Pathologic T stage			0.4
T0/Tis	27 (23%)	6 (27%)
T1	69 (60%)	11 (50%)
T2	13 (11%)	5 (23%)
T3	6 (5.2%)	0 (0%)
Unknown	1	0
Pathologic N stage			0.4
N0	85 (75%)	14 (67%)
N1	21 (18%)	6 (29%)
N2	6 (5.3%)	0 (0%)
N3	2 (1.8%)	1 (4.8%)
Unknown	2	1
Bilateral salpingo-oophorectomy	18 (17%)	2 (11%)	0.7
Unknown	7	3

Data expressed as n (%) unless otherwise indicated.

Bolded values indicate statistical significance.

UVA univariable, VUS variant of uncertain significance, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, HR hormone receptor, HER2 human epidermal growth factor receptor 2